Vitality Watch

Dossier clinicaltrials trial early 01-jul-2026
Small or early-phase human trial or pilot study

Evaluation of AppleX™ Apple Extract on Anti-Inflammatory and Healthy Aging Effects

Key claim: A placebo-controlled clinical trial is testing whether daily AppleX™ apple extract lowers hsCRP and improves fatigue, joint comfort, and biological/epigenetic aging metrics in adults aged 45–70 with low-grade inflammation.

Abstract

The goal of this clinical trial is to learn if AppleX™ Apple Extract can help lower systemic inflammation in adults aged 45-70 with signs of low-grade inflammation. It will also look at the extract’s effects on fatigue, joint comfort, and biological aging metrics.

The main questions it aims to answer are:

  • Does taking AppleX™ Apple Extract daily lower high-sensitivity C-reactive protein (hsCRP) levels, a key marker of inflammation in the blood?
  • Does AppleX™ Apple Extract improve participant-reported fatigue and joint comfort?
  • Does the extract slow down biological or epigenetic aging metrics compared to a placebo?

Researchers will compare AppleX™ Apple Extract to a placebo (a look-alike capsule that contains no active ingredients) to see if the apple extract has a measurable anti-inflammatory and healthy aging effect.

Why this matters

A placebo-controlled clinical trial is testing whether daily AppleX™ apple extract lowers hsCRP and improves fatigue, joint comfort, and biological/epigenetic aging metrics in adults aged 45–70 with low-grade inflammation.

Source

Link

Briefing card

Evaluation of AppleX™ Apple Extract on Anti-Inflammatory and Healthy Aging Effects
Stage: trial early · clinicaltrials · 01-jul-2026

A placebo-controlled clinical trial is testing whether daily AppleX™ apple extract lowers hsCRP and improves fatigue, joint comfort, and biological/epigenetic aging metrics in adults aged 45–70 with low-grade inflammation.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT07678346

build build 880 · 2bcef25 · 2026-11-18